136 related articles for article (PubMed ID: 25707961)
1. Assessments of antibody biodistribution.
Glassman PM; Abuqayyas L; Balthasar JP
J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S29-38. PubMed ID: 25707961
[TBL] [Abstract][Full Text] [Related]
2. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
Glassman PM; Balthasar JP
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibody pharmacokinetics and pharmacodynamics.
Wang W; Wang EQ; Balthasar JP
Clin Pharmacol Ther; 2008 Nov; 84(5):548-58. PubMed ID: 18784655
[TBL] [Abstract][Full Text] [Related]
4. Physiologically-based modeling to predict the clinical behavior of monoclonal antibodies directed against lymphocyte antigens.
Glassman PM; Balthasar JP
MAbs; 2017; 9(2):297-306. PubMed ID: 27892793
[TBL] [Abstract][Full Text] [Related]
5. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.
Wang J; Iyer S; Fielder PJ; Davis JD; Deng R
Biopharm Drug Dispos; 2016 Mar; 37(2):51-65. PubMed ID: 25869767
[TBL] [Abstract][Full Text] [Related]
6. Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.
Glassman PM; Chen Y; Balthasar JP
J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):527-40. PubMed ID: 26364301
[TBL] [Abstract][Full Text] [Related]
7. Preclinical characterization of the ADME properties of a surrogate anti-IL-36R monoclonal antibody antagonist in mouse serum and tissues.
Conner KP; Pastuskovas CV; Soto M; Thomas VA; Wagner M; Rock DA
MAbs; 2020; 12(1):1746520. PubMed ID: 32310023
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
[TBL] [Abstract][Full Text] [Related]
9. Issues, challenges, and opportunities in model-based drug development for monoclonal antibodies.
Hu L; Hansen RJ
J Pharm Sci; 2013 Sep; 102(9):2898-908. PubMed ID: 23508847
[TBL] [Abstract][Full Text] [Related]
10. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
Gurbaxani B; Dostalek M; Gardner I
Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.
Dostalek M; Gardner I; Gurbaxani BM; Rose RH; Chetty M
Clin Pharmacokinet; 2013 Feb; 52(2):83-124. PubMed ID: 23299465
[TBL] [Abstract][Full Text] [Related]
12. Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini-review on fundamental concepts and applications.
Ferl GZ; Theil FP; Wong H
Biopharm Drug Dispos; 2016 Mar; 37(2):75-92. PubMed ID: 26461173
[TBL] [Abstract][Full Text] [Related]
13. Target-mediated drug disposition model for drugs that bind to more than one target.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
[TBL] [Abstract][Full Text] [Related]
14. Antibody pharmacokinetics and pharmacodynamics.
Lobo ED; Hansen RJ; Balthasar JP
J Pharm Sci; 2004 Nov; 93(11):2645-68. PubMed ID: 15389672
[TBL] [Abstract][Full Text] [Related]
15. Influence of molecular size on tissue distribution of antibody fragments.
Li Z; Krippendorff BF; Sharma S; Walz AC; Lavé T; Shah DK
MAbs; 2016; 8(1):113-9. PubMed ID: 26496429
[TBL] [Abstract][Full Text] [Related]
16. Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development.
Glassman PM; Balthasar JP
Drug Metab Pharmacokinet; 2019 Feb; 34(1):3-13. PubMed ID: 30522890
[TBL] [Abstract][Full Text] [Related]
17. Application of a catenary PBPK model to predict the disposition of "catch and release" anti-PCSK9 antibodies.
Glassman PM; Balthasar JP
Int J Pharm; 2016 May; 505(1-2):69-78. PubMed ID: 27041125
[TBL] [Abstract][Full Text] [Related]
18. Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human.
Shah DK; Betts AM
MAbs; 2013; 5(2):297-305. PubMed ID: 23406896
[TBL] [Abstract][Full Text] [Related]
19. Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors.
Sung C; Shockley TR; Morrison PF; Dvorak HF; Yarmush ML; Dedrick RL
Cancer Res; 1992 Jan; 52(2):377-84. PubMed ID: 1728409
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies.
Lin JH
Curr Drug Metab; 2009 Sep; 10(7):661-91. PubMed ID: 19702530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
